Outcomes of age-based and precision screening compared with no screening.

Outcomes of age-based and precision screening compared with no screening.</p

Model parameters.

Model parameters.</p

Incremental cost and QALYs of precision and age-based screening compared with no screening.

Results based on 10,000 simulations. The solid lines describe the incremental costs incurred and QALYs gained of precision screening versus no screening, whilst the dashed lines represent the incremental costs and QALYs of age-based versus no screening. QALY, quality-adjusted life-year.</p

Overdiagnosed cases and prostate cancer deaths prevented with precision screening as compared to age-based screening.

Results based on 10,000 simulations.</p

Additional file 1 of Genomic risk prediction of coronary artery disease in women with breast cancer: a prospective cohort study

Additional file 1. Supplementary appendix containing additional description of methods and tables and figures for sensitivity analyses described in the main text

Supplementary Figure S3 from The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

BRCA1-minigene analyses.</p

Supplementary Figure S5 from The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Ectopic BRCA1-Deltaq expression promotes resistance in additional cell line backgrounds.</p

Additional file 3 of PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients

Additional file 1: Table S3. Patient and primary breast cancer characteristics per study

Supplementary Figure Legends from The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Legend for Supplementary Figures S1-S6.</p

Supplementary Figure S1 from The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

BRCA1-Delta11q mRNA and protein isoform.</p